Search

Relay Therapeutics Inc

Chiusa

SettoreSettore sanitario

17.46 -1.41

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

17.39

Massimo

17.91

Metriche Chiave

By Trading Economics

Entrata

-10M

-84M

Vendite

-2.7M

350K

EPS

-0.41

Margine di Profitto

-23,916.286

Dipendenti

202

EBITDA

-10M

-83M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+53.22% upside

Dividendi

By Acuity

Utili prossimi

5 nov 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-107M

4B

Apertura precedente

18.87

Chiusura precedente

17.46

Notizie sul Sentiment di mercato

By Acuity

50%

50%

118 / 339 Classifica in Healthcare

Relay Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

24 set 2026, 19:46 UTC

Social Media

Relay Therapeutics shares fell amid expectations for data release, despite significant call buying and potential $400 million funding from Elevar if approved this week.

23 set 2026, 23:20 UTC

Relay Therapeutics Inc is gaining in after-market trading, moving from a low return to a peak, currently around the middle of its one-month trading range.

22 set 2026, 20:07 UTC

Relay Therapeutics Inc shares are rising sharply, benefiting from strong market momentum and remaining above their 20-day moving average since Monday's close.

21 set 2026, 20:06 UTC

Relay Therapeutics Inc shares fell sharply, closing near the lower end of their one-month range and significantly below the 20-day moving average.

18 set 2026, 20:06 UTC

Relay Therapeutics Inc shares fell sharply after an early peak, trading below its 20-day moving average and near the lower end of its one-month range.

17 set 2026, 19:46 UTC

Relay Therapeutics Inc is trading higher, having reached a peak earlier before pulling back, and has gained since Wednesday's close.

16 set 2026, 20:13 UTC

Relay Therapeutics Inc saw modestly lower trading during after-market hours, remaining unchanged since Wednesday's close and below its 20-day moving average.

15 set 2026, 19:46 UTC

Relay Therapeutics Inc shares are lower, reflecting negative market sentiment after the NY Empire State Manufacturing Index fell sharply to 7.6 for September.

14 set 2026, 20:21 UTC

Relay Therapeutics Inc. shares advanced in after-market trading, rebounding from earlier lows and reflecting a shift within a routine range since Monday's close.

10 set 2026, 19:16 UTC

Relay Therapeutics Inc is trading higher, recovering from an earlier dip. No specific news was identified, though broader market sentiment may be influencing shares.

9 set 2026, 23:31 UTC

Relay Therapeutics Inc is trading higher in after-market hours, advancing since Wednesday's close despite a broader market decline amid rising oil prices and inflation concerns.

8 set 2026, 20:07 UTC

News

Relay Therapeutics shares are higher, continuing an upward trend since Friday's close, though they remain below the 20-day moving average.

2 set 2026, 20:08 UTC

News

Relay Therapeutics will participate in two investor conferences in September 2026. Shares are trading roughly flat since Tuesday's close, below the 20-day moving average.

31 ago 2026, 20:07 UTC

Relay Therapeutics shares are lower today amid broader market pressures and concerns about inflation following the Jackson Hole Economic Symposium.

28 ago 2026, 21:51 UTC

Relay Therapeutics Inc is trading higher in after-market hours, rebounding from three consecutive lower sessions. No specific news was identified for this movement.

27 ago 2026, 22:01 UTC

Relay Therapeutics Inc shares are lower in after-market trading, declining from earlier gains amid broader weakness and three consecutive sessions of losses.

26 ago 2026, 20:08 UTC

Relay Therapeutics Inc is trading lower today amid broader market declines, influenced by inflation data that exceeded expectations and may impact Federal Reserve policy.

25 ago 2026, 23:41 UTC

Relay Therapeutics Inc shares are lower in after-market hours, with no specific news identified for the decline. The stock remains above its 20-day moving average.

24 ago 2026, 19:56 UTC

Social Media

Relay Therapeutics is testing a buy point at $20.79, reflecting ongoing interest. The stock remains higher since Friday's close despite an earlier pullback.

21 ago 2026, 21:01 UTC

Relay Therapeutics Inc is trading higher in after-market hours, up significantly since Friday's close and above its 20-day moving average.

20 ago 2026, 20:02 UTC

Correlated Moves

Relay Therapeutics Inc shares are lower today, influenced by a decline in the broader Biotechnology sector and significant market volatility. Trading volume remains unusually high.

19 ago 2026, 23:01 UTC

Relay Therapeutics Inc is trading higher in after-market hours, positioned near the upper end of its one-month range and above its 20-day moving average.

18 ago 2026, 22:26 UTC

Relay Therapeutics Inc. shares traded lower after market hours, reflecting broader market pressure from rising bond yields and inflation concerns.

17 ago 2026, 19:36 UTC

Social Media
News

Relay Therapeutics Inc is trading higher amid a Phase 3 trial for its breast cancer treatment and a $53 million investment from Baker Bros.

14 ago 2026, 21:51 UTC

Social Media

Relay Therapeutics Inc is gaining in after-market trading, supported by social media discussions and a significant portfolio stake from Perceptive Advisors.

13 ago 2026, 19:16 UTC

Correlated Moves

Relay Therapeutics Inc is trading lower, reflecting broader declines in the biotechnology sector amid fluctuations and rising initial jobless claims.

10 ago 2026, 19:56 UTC

News
Social Media

Relay Therapeutics shares are higher after Citizens raised its price target to $26, citing confidence in the company's Phase 3 trials.

7 ago 2026, 20:06 UTC

News
Correlated Moves
Social Media

Barclays raised its price target on Relay Therapeutics to $30.00, contributing to positive sentiment amid ongoing analyst support following the company's Q2 earnings.

6 ago 2026, 23:02 UTC

News

Relay Therapeutics shares are lower in after-market hours following disappointing Q2 results, including a net loss of $83.7 million and revenue of $350,000.

5 ago 2026, 22:26 UTC

Relay Therapeutics Inc. shares advanced in after-market trading, maintaining a position above its 20-day moving average amid broader macroeconomic sentiment.

Confronto tra pari

Modifica del prezzo

Relay Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

53.22% in crescita

Previsioni per 12 mesi

Media 27.625 USD  53.22%

Alto 31 USD

Basso 20 USD

Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Relay Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

9 ratings

9

Acquista

0

Mantieni

0

Vendi

Sentiment

By Acuity

118 / 339 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Relay Therapeutics Inc

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.